Drew Moghanaki/X
Jun 18, 2025, 18:12
Drew Moghanaki: UPMC Phase II Study on Head and Neck Cancers and the Future of Immunotherapy in ChemoRT
Drew Moghanaki, Chief Medical Officer at Respirati and Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at David Geffen School of Medicine at UCLA, shared a post on X:
“From my perspective, this UPMC phase II study for Head and Neck cancers is a landmark randomized clinical trial, even though it enrolled only 80 participants. It establishes a potentially final deterrent for investigators considering future studies combining concurrent immune checkpoint inhibitors during chemoRT for any cancer. I predict that the way forward will be sequential immunotherapy with chemoRT investigating newer drug combinations.”
Title: Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer
Authors: Dan P. Zandberg, Lazar Vujanovic, David A. Clump, Brian P. Isett, Hong Wang, Gabriel Sica, Riyue Bao, Housayin Li, James Ohr, Heath D. Skinner, Raja R. Seethala, Simion I. Chiosea, Robert L. Ferris, Julie E. Bauman
Read the Full Article.
More posts featuring Drew Moghanaki.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 19, 2025, 08:24
Jun 19, 2025, 08:05
Jun 19, 2025, 08:01
Jun 19, 2025, 07:51
Jun 19, 2025, 07:49